A promising new cancer marker: Long noncoding RNA EGFR-AS1

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Cancer is characterized by uncontrolled cell cycles, metastasis, and immune evasion, often driven by genomic instability.
• Long noncoding RNAs (lncRNAs) are key regulators in disease, impacting clinical features and pathological processes.
• Aberrant expression of lncRNAs is increasingly recognized in various diseases, including cancers.

Purpose of the Study:

• To review the expression profile, molecular mechanisms, biological functions, and clinical value of EGFR-AS1 in cancers.
• To highlight EGFR-AS1 as a potential biomarker for cancer management.

Main Methods:

• Literature review of studies investigating EGFR-AS1 in cancer.
• Analysis of expression patterns, functional roles, and clinical correlations of EGFR-AS1.

Main Results:

• EGFR-AS1 is aberrantly expressed in multiple cancer types and correlates with clinical characteristics.
• EGFR-AS1 regulates crucial cellular activities such as proliferation, invasion, migration, chemosensitivity, and stemness.
• EGFR-AS1 is implicated in diverse biological and pathological cancer processes.

Conclusions:

• EGFR-AS1 plays a significant role in cancer development and progression.
• EGFR-AS1 holds promise as a diagnostic and prognostic biomarker for cancer management.